Abbott shares face cautious technical signals after nearly 2% gain: weekly analysis

Traders Union
All News
Stocks
Abbott Laboratories gains 1.93% this week

Highlights

Abbott shares have risen 1.93% over the past week and are showing renewed short-term strength after surpassing major averages.
Technical momentum is building but remains unconfirmed, with several indicators nearing overbought levels, signaling heightened caution if the rally persists.
Traders expect price consolidation between $104.65 and $110.92, with a bullish breakout likely if resistance at $108.35 is cleared.

Profit outlook raised amid sales growth and new diagnostics catalyst this week

Abbott reported second-quarter 2026 results with sales rising to $12.59 billion from $11.14 billion a year earlier, even as net income and diluted EPS decreased, according to Simply Wall St News. The company raised its annual profit outlook following strong performance in diagnostics and medical devices, Yahoo Finance reported. Yahoo Finance also noted Abbott's exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, an FDA-approved colorectal cancer screening test, adding a further boost to its diagnostics business. Ongoing litigation risks and discussions around dividend payout ratios drew some attention in industry commentary.

Overbought signals emerge as momentum and volatility climb during week

The daily chart signals a developing trend, with momentum showing an emerging move higher that is not yet confirmed. RSI is at 66.86 and CCI at 82.68, both approaching overbought territory, which could signal caution if the rally continues. Bull/Bear Power is in overbought territory, reinforcing strong buyer dominance, while volatility over the past week has been elevated at 6.79%. Nearest support is at $103.04, with resistance aligning directly at the 200-day moving average of $108.35 and the Ichimoku Kijun providing an additional support reference at $98.84.

Bullish scenario holds if resistance breaks in the coming week

Over the coming trading week, Abbott shares are expected to move within a $104.65 to $110.92 range. There is a 75% probability of an increase and a 25% chance of a decrease. The base case is for price action to consolidate inside the range, with upward follow-through likely if shares clear resistance at $108.35. A bullish break above $110.92 would open further upside. If the price falls below $103.04 support, short-term sentiment could quickly turn more cautious.

Anton Kharitonov, expert at Traders Union, notes that Abbott Laboratories (ABT) delivered a strong week, but technicals show early signs of exhaustion near resistance. He believes the momentum from solid sales and favorable news in diagnostics could help maintain buyer confidence, but overbought signals and an elevated RSI warrant caution. The analyst points to the $108.35 level as crucial; if ABT fails to clear this resistance, a period of range trading or consolidation is likely. Although the raised profit outlook and new product rights support fundamentals, ongoing litigation risks may keep sentiment from turning overly bullish. The base scenario for the coming week is sideways action in the $104.65 to $110.92 range. "Until Abbott can break through $108.35 with conviction, I remain cautious and prefer to wait for clearer confirmation before expecting further gains."

Earlier, analysts noted that Abbott Laboratories was exhibiting short-term bullish momentum but faced potential constraints due to persistent long-term resistance. The latest developments, including improved earnings and expanded diagnostics partnerships, reinforce the case for continued upside, with sustained gains hinging on a decisive breakout above $110.92.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.